Based in Melbourne, Australia, Patrys is a publicly-listed company on the Australian Securities Exchange (ASX: PAB) drug development company focused on commercialising antibody therapies for oncology. Listed since 2007, Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy. Patrys has successfully out-licensed a clinical candidate for the Chinese market and conducted two clinical trials with another lead candidate from its IgM platform. More recently, Patrys in-licensed from Yale University a suite of novel nucleus-penetrating antibodies (Deoxymab and 5C6) which it will progress through development. Patrys will continue to advance lead candidates from both its technology platforms towards the market, either self-funded or co-developed, and welcomes discussions with interested parties on development.
Company Details
- Employees
- 5
- Founded
- 2007
- Address
- Level 4, 100 Albert Road, South Melbourne, Melbourne,vic 3205,australia
- Phone
- 61 3 9670 3273
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- patrys.com
- HQ
- Melbourne, VIC
Patrys Limited Questions
Patrys Limited's helpline number is 61 3 9670 3273
Patrys Limited's website is patrys.com
Patrys Limited's LinkedIn profile is https://au.linkedin.com/company/patrys-limited
Patrys Limited has
5 employees.
View email and phone details for 5
employees at Patrys Limited.
Patrys Limited's industry is
Biotechnology Research
Patrys Limited's top competitors are
Noxopharm Limited,
Paradigm Biopharmaceuticals,
Cartherics Pty Ltd,
T-Curx Gmbh,
Kinoxis Therapeutics Pty Ltd,
Oncosil Medical,
Percheron Therapeutics Limited,
Cyclotek Pty Ltd,
Prescient Therapeutics,
Nyrada Inc. (Asx:nyr).
Patrys Limited's categories are Biotechnology Research
Patrys Limited's founding year is 2007
